NCT04948138 is a NA clinical trial of Glutamine oral supplementation in MELAS Syndrome, sponsored by Jesús González de la Aleja Tejera.

Who is sponsoring NCT04948138?

NCT04948138 is sponsored by Jesús González de la Aleja Tejera.

What drugs are being tested in NCT04948138?

Interventions in NCT04948138: Glutamine oral supplementation.

What condition does NCT04948138 study?

NCT04948138 studies MELAS Syndrome.

Is NCT04948138 still recruiting?

NCT04948138 is currently completed. Last updated 24 February 2022.

Last reviewed 2022-02-24 · How we verify

NCT04948138

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome

Completed NA Last updated 24 February 2022

What this trial tests

NA trial testing Glutamine oral supplementation in MELAS Syndrome in 9 participants. Completed in 6 October 2021.

Timeline

28 June 2021

Primary endpoint
9 September 2021

6 October 2021

Quick facts

Lead sponsor	Jesús González de la Aleja Tejera
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	28 June 2021
Primary completion	9 September 2021
Estimated completion	6 October 2021
Sites	1 location across Spain

Drugs / interventions tested

Glutamine oral supplementation

Conditions studied

MELAS Syndrome — all drugs for MELAS Syndrome →

Sponsor

Jesús González de la Aleja Tejera

Who can join

18 and older, any sex, with MELAS Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assesses the efficacy of oral supplementation with glutamine over three months on several amino acids and lactate concentration measured in cerebrospinal fluid and cerebral lactate measured by magnetic resonance spectroscopy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

High-dose oral glutamine supplementation reduces elevated glutamate levels in cerebrospinal fluid in patients with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome.
Guerrero-Molina MP, Morales-Conejo M, Delmiro A, Morán M, et al · · 2023 · cited 6× · PMID 36334048 · DOI 10.1111/ene.15626
Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review.
Hustinx M, Shorrocks AM, Servais L. · · 2023 · cited 4× · PMID 37376074 · DOI 10.3390/pharmaceutics15061626
Magnetic resonance spectroscopy in MELAS syndrome: correlation with CSF and plasma metabolite levels and change after glutamine supplementation.
Guerrero-Molina MP, Bernabeu-Sanz Á, Ramos-González A, Morales-Conejo M, et al · · 2024 · cited 1× · PMID 38114794 · DOI 10.1007/s00234-023-03263-1

Verify or expand the search:

Other recruiting trials for MELAS Syndrome

Currently open trials in the same condition.

NCT06644534 — A Study to Assess TTI-0102 vs Placebo in MELAS Patients · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04948138 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jesús González de la Aleja Tejera
Last refreshed: 24 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04948138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing